ID

DB00233|APRD00749|EXPT00693|

名称

Aminosalicylic acid

描述

An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.

cas号

65-49-6

唯一标识码

5B2658E0N2

状态

solid

组

approved,

指示

For the treatment of tuberculosis

药效学

Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs (most often isoniazid) for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The two major considerations in the clinical pharmacology of aminosalicylic acid are the prompt production of a toxic inactive metabolite under acid conditions and the short serum half life of one hour for the free drug. Aminosalicylic acid is bacteriostatic against Mycobacterium tuberculosis (prevents the multiplying of bacteria without destroying them). It also inhibits the onset of bacterial resistance to streptomycin and isoniazid.

作用机制

There are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against Mycobacterium tuberculosis. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The binding of para-aminobenzoic acid to pteridine synthetase acts as the first step in folic acid synthesis. Aminosalicylic acid binds pteridine synthetase with greater affinity than para-aminobenzoic acid, effectively inhibiting the synthesis of folic acid. As bacteria are unable to use external sources of folic acid, cell growth and multiplication slows. Secondly, aminosalicylic acid may inhibit the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis.

毒性

LD₅₀=4 gm/kg (orally in mice); LD₅₀=3650 mg/kg (orally in rabbits)

代谢

Hepatic.

吸收

半衰期

分类

description:This compound belongs to the class of organic compounds known as aminosalicylic acids. These are salicylic acids carrying an amino group on the benzene ring.
direct-parent:Aminosalicylic acids
kingdom:Organic compounds
superclass:Benzenoids
class:Benzene and substituted derivatives
subclass:Benzoic acids and derivatives
alternative-parent:1-hydroxy-2-unsubstituted benzenoids
alternative-parent:1-hydroxy-4-unsubstituted benzenoids
alternative-parent:4-aminosalicylic acids
alternative-parent:Amino acids
alternative-parent:Aminobenzoic acids
alternative-parent:Aniline and substituted anilines
alternative-parent:Benzoic acids
alternative-parent:Benzoyl derivatives
alternative-parent:Carboxylic acids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organooxygen compounds
alternative-parent:Organopnictogen compounds
alternative-parent:Primary amines
alternative-parent:Salicylic acids
alternative-parent:Vinylogous acids
alternative-parent:m-Aminophenols
substituent:1-hydroxy-2-unsubstituted benzenoid
substituent:1-hydroxy-4-unsubstituted benzenoid
substituent:4-aminosalicylic acid
substituent:Amine
substituent:Amino acid
substituent:Amino acid or derivatives
substituent:Aminobenzoic acid
substituent:Aminobenzoic acid or derivatives
substituent:Aminophenol
substituent:Aminosalicylic acid
substituent:Aniline or substituted anilines
substituent:Aromatic homomonocyclic compound
substituent:Benzoic acid
substituent:Benzoyl
substituent:Carboxylic acid
substituent:Carboxylic acid derivative
substituent:Hydrocarbon derivative
substituent:M-aminophenol
substituent:Monocarboxylic acid or derivatives
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Phenol
substituent:Primary amine
substituent:Salicylic acid
substituent:Vinylogous acid

消除途径

种类

Acids, Carbocyclic
D000146
Aminobenzoates
D062365
Aminosalicylic Acid and Derivatives

Aminosalicylic Acids
D000636
Anti-Bacterial Agents
D000900
Anti-Infective Agents
D000890
Antiinfectives for Systemic Use

Antimycobacterials

Antituberculosis Agents
D000995
Benzene Derivatives
D001555
Benzoates
D001565
Drugs for Treatment of Tuberculosis

Hydroxy Acids
D006880
Hydroxybenzoates
D062385
para-Aminobenzoates
D062366
Phenols
D010636
Salicylates
D012459

盐类

DBSALT001939Aminosalicylate calcium73I4QDW01W133-15-3XDWVNCOPMIEDJK-UHFFFAOYSA-L344.336344.032127DBSALT000354Aminosalicylate sodium anhydrousT9ZKL3TNQF133-10-8FVVDKUPCWXUVNP-UHFFFAOYSA-M175.1172175.024537738DBSALT001940Calcium aminosalicylate trihydrate9VF16M7FWU6059-16-1IPLQYSPEGHNJCQ-UHFFFAOYSA-L398.381398.0638211DBSALT002415Potassium aminosalicylate7N21461LKD133-09-5PRZJIMSXCLZGLT-UHFFFAOYSA-M191.227190.99847455DBSALT001938Sodium aminosalicylate dihydrateS38B9W6AXW6018-19-5GMUQJDAYXZXBOT-UHFFFAOYSA-M211.149211.04566671

蛋白质结合

50-60%

清除

同义词

language:english; code:iupac; name;4-amino-2-hydroxybenzoic acid
language:english; code:; name;4-aminosalicylate
language:english; code:; name;4-aminosalicylic acid
language:english; code:usp; name;Aminosalicylic acid
language:english; code:; name;p-aminosalicylic acid
language:english; code:; name;para-amino salicylic acid
language:english; code:; name;para-aminosalicylic acid
language:english; code:; name;PAS

国际品牌

PamisylParke-DavisRexipasBristol-Myers SquibbRezipasBristol-Myers Squibb

配送量

产品

name:Granupas
labeller:Eurocept International B. V.
ndc-id:
ndc-product-code:
dpd-id:
ema-product-code:EMEA/H/C/002709
ema-ma-number:EU/1/13/896/001
started-marketing-on:2014-04-07
ended-marketing-on:
dosage-form:Granule, delayed release
strength:4 g
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:EU
source:EMA
name:Nemasol Sodium Tab 500mg
labeller:Icn Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:00236691
ema-product-code:
ema-ma-number:
started-marketing-on:1966-12-31
ended-marketing-on:2005-04-26
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Paser
labeller:Jacobus Pharmaceutical
ndc-id:
ndc-product-code:49938-107
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1995-02-15
ended-marketing-on:
dosage-form:Granule, delayed release
strength:4 g/1
route:Oral
fda-application-number:ANDA074346
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC

混合物

name:Granupas
ingredients:Aminosalicylic acid
name:Paser
ingredients:Aminosalicylic acid
name:Nemasol Sodium Tab 500mg
ingredients:Aminosalicylic acid

包装者

name:Jacobus Pharmaceutical Co.
url:
name:Medisca Inc.
url:http://www.medisca.com
name:Professional Co.
url:
name:Spectrum Pharmaceuticals
url:http://www.spectrumpharm.com

生产者

generic:否; url:; name;Century pharmaceuticals inc
generic:否; url:; name;Hexcel chemical products
generic:否; url:; name;Panray corp sub ormont drug and chemical co inc
generic:否; url:; name;Lannett co inc
generic:否; url:; name;Consolidated midland corp
generic:否; url:; name;Jacobus pharmaceutical co
generic:否; url:; name;Bristol myers squibb co

价格

Aminosalicylic acid powder
2.4(单位：USD）
g
Paser granules 4 gm packet
3.59(单位：USD）
packet

受影响的生物体

Mycobacteria

剂量

form:Granule
route:Oral
strength:4 G
form:Granule, delayed release
route:Oral
strength:4 g
form:Granule
route:Oral
strength:60 g
form:Tablet
route:Oral
strength:
form:Tablet, delayed release
route:Oral
strength:1 g
form:Tablet
route:Oral
strength:1 g
form:Tablet
route:Oral
strength:1 gr
form:Granule, delayed release
route:Oral
strength:4 g/1

atc代码

Aminosalicylic acid and derivatives
DRUGS FOR TREATMENT OF TUBERCULOSIS
ANTIMYCOBACTERIALS
ANTIINFECTIVES FOR SYSTEMIC USE
Aminosalicylic acid and derivatives
DRUGS FOR TREATMENT OF TUBERCULOSIS
ANTIMYCOBACTERIALS
ANTIINFECTIVES FOR SYSTEMIC USE
Aminosalicylic acid and derivatives
DRUGS FOR TREATMENT OF TUBERCULOSIS
ANTIMYCOBACTERIALS
ANTIINFECTIVES FOR SYSTEMIC USE

fda标签

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00233.pdf?1265922740

专利

食物相互作用

Take with or without food. The absorption is unaffected by food.

药物相互作用

DB06767
The serum concentration of Aminosalicylic acid can be increased when it is combined with Ammonium chloride.
DB01381
Ginkgo biloba may increase the anticoagulant activities of Aminosalicylic acid.
DB00563
The serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic acid.
DB06813
The serum concentration of Pralatrexate can be increased when it is combined with Aminosalicylic acid.
DB01032
The therapeutic efficacy of Probenecid can be decreased when used in combination with Aminosalicylic acid.
DB00374
The risk or severity of bleeding can be increased when Treprostinil is combined with Aminosalicylic acid.
DB09268
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aminosalicylic acid.
DB01009
The risk or severity of bleeding and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Ketoprofen.
DB09214
The risk or severity of bleeding and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Dexketoprofen.
DB00266
Aminosalicylic acid may increase the anticoagulant activities of Dicoumarol.
DB00498
Aminosalicylic acid may increase the anticoagulant activities of Phenindione.
DB00682
Aminosalicylic acid may increase the anticoagulant activities of Warfarin.
DB00946
Aminosalicylic acid may increase the anticoagulant activities of Phenprocoumon.
DB01418
Aminosalicylic acid may increase the anticoagulant activities of Acenocoumarol.
DB03410
Aminosalicylic acid may increase the anticoagulant activities of 4-hydroxycoumarin.
DB04665
Aminosalicylic acid may increase the anticoagulant activities of Coumarin.
DB08496
Aminosalicylic acid may increase the anticoagulant activities of (R)-warfarin.
DB08794
Aminosalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
DB13136
Aminosalicylic acid may increase the anticoagulant activities of Fluindione.
DB13275
Aminosalicylic acid may increase the anticoagulant activities of Clorindione.
DB13347
Aminosalicylic acid may increase the anticoagulant activities of Diphenadione.
DB13451
Aminosalicylic acid may increase the anticoagulant activities of Tioclomarol.
DB14055
Aminosalicylic acid may increase the anticoagulant activities of (S)-Warfarin.
DB00390
The serum concentration of Digoxin can be decreased when it is combined with Aminosalicylic acid.
DB00511
The serum concentration of Acetyldigitoxin can be decreased when it is combined with Aminosalicylic acid.
DB01078
The serum concentration of Deslanoside can be decreased when it is combined with Aminosalicylic acid.
DB01092
The serum concentration of Ouabain can be decreased when it is combined with Aminosalicylic acid.
DB01396
The serum concentration of Digitoxin can be decreased when it is combined with Aminosalicylic acid.
DB12843
The serum concentration of Oleandrin can be decreased when it is combined with Aminosalicylic acid.
DB13240
The serum concentration of Cymarin can be decreased when it is combined with Aminosalicylic acid.
DB13307
The serum concentration of Proscillaridin can be decreased when it is combined with Aminosalicylic acid.
DB13401
The serum concentration of Metildigoxin can be decreased when it is combined with Aminosalicylic acid.
DB13467
The serum concentration of Lanatoside C can be decreased when it is combined with Aminosalicylic acid.
DB13537
The serum concentration of Gitoformate can be decreased when it is combined with Aminosalicylic acid.
DB13691
The serum concentration of Acetyldigoxin can be decreased when it is combined with Aminosalicylic acid.
DB13756
The serum concentration of Peruvoside can be decreased when it is combined with Aminosalicylic acid.
DB00352
The metabolism of Tioguanine can be decreased when combined with Aminosalicylic acid.
DB00993
The metabolism of Azathioprine can be decreased when combined with Aminosalicylic acid.
DB01033
The metabolism of Mercaptopurine can be decreased when combined with Aminosalicylic acid.
DB00001
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.
DB00006
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bivalirudin.
DB00009
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Alteplase.
DB00013
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Urokinase.
DB00015
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reteplase.
DB00029
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Anistreplase.
DB00031
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tenecteplase.
DB00054
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Abciximab.
DB00055
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Drotrecogin alfa.
DB00086
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Streptokinase.
DB00278
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Argatroban.
DB00407
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ardeparin.
DB00569
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Fondaparinux.
DB00686
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Pentosan polysulfate.
DB00975
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dipyridamole.
DB01088
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Iloprost.
DB01109
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Heparin.
DB01225
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Enoxaparin.
DB01240
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Epoprostenol.
DB04898
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ximelagatran.
DB04925
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Desmoteplase.
DB04932
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Defibrotide.
DB05099
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ancrod.
DB05229
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Beraprost.
DB05254
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Fibrinolysin.
DB06209
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Prasugrel.
DB06228
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Rivaroxaban.
DB06271
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sulodexide.
DB06294
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Semuloparin.
DB06406
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Idraparinux.
DB06441
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Cangrelor.
DB06543
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Astaxanthin.
DB06605
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Apixaban.
DB06635
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Otamixaban.
DB06679
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Amediplase.
DB06695
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran etexilate.
DB06754
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Danaparoid.
DB06779
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dalteparin.
DB06822
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tinzaparin.
DB07767
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ferulic acid.
DB08813
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Nadroparin.
DB08814
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Triflusal.
DB08816
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ticagrelor.
DB08994
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ditazole.
DB09030
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Vorapaxar.
DB09075
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edoxaban.
DB09125
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Potassium citrate.
DB09154
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sodium citrate.
DB09255
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dextran.
DB09258
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bemiparin.
DB09260
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Parnaparin.
DB11095
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Desirudin.
DB11154
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Zinc citrate.
DB11166
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin Alfa.
DB11312
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Protein C.
DB11598
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin III human.
DB11984
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Letaxaban.
DB12289
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Darexaban.
DB12364
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Betrixaban.
DB12598
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Nafamostat.
DB12726
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Monteplase.
DB12831
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Gabexate.
DB13149
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Protein S human.
DB13199
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Brinase.
DB13616
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Melagatran.
DB13646
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Saruplase.
DB14094
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tocopherylquinone.
DB14598
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edetate calcium disodium anhydrous.
DB14726
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran.
DB13124
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Troxerutin.
DB00974
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edetic acid.
DB09259
The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reviparin.
DB00030
Aminosalicylic acid may increase the hypoglycemic activities of Insulin human.
DB00046
Aminosalicylic acid may increase the hypoglycemic activities of Insulin lispro.
DB00047
Aminosalicylic acid may increase the hypoglycemic activities of Insulin glargine.
DB00071
Aminosalicylic acid may increase the hypoglycemic activities of Insulin pork.
DB00197
Aminosalicylic acid may increase the hypoglycemic activities of Troglitazone.
DB00222
Aminosalicylic acid may increase the hypoglycemic activities of Glimepiride.
DB00263
Aminosalicylic acid may increase the hypoglycemic activities of Sulfisoxazole.
DB00280
Aminosalicylic acid may increase the hypoglycemic activities of Disopyramide.
DB00284
Aminosalicylic acid may increase the hypoglycemic activities of Acarbose.
DB00331
Aminosalicylic acid may increase the hypoglycemic activities of Metformin.
DB00359
Aminosalicylic acid may increase the hypoglycemic activities of Sulfadiazine.
DB00412
Aminosalicylic acid may increase the hypoglycemic activities of Rosiglitazone.
DB00414
Aminosalicylic acid may increase the hypoglycemic activities of Acetohexamide.
DB00468
Aminosalicylic acid may increase the hypoglycemic activities of Quinine.
DB00491
Aminosalicylic acid may increase the hypoglycemic activities of Miglitol.
DB00672
Aminosalicylic acid may increase the hypoglycemic activities of Chlorpropamide.
DB00731
Aminosalicylic acid may increase the hypoglycemic activities of Nateglinide.
DB00738
Aminosalicylic acid may increase the hypoglycemic activities of Pentamidine.
DB00834
Aminosalicylic acid may increase the hypoglycemic activities of Mifepristone.
DB00839
Aminosalicylic acid may increase the hypoglycemic activities of Tolazamide.
DB00912
Aminosalicylic acid may increase the hypoglycemic activities of Repaglinide.
DB00914
Aminosalicylic acid may increase the hypoglycemic activities of Phenformin.
DB01015
Aminosalicylic acid may increase the hypoglycemic activities of Sulfamethoxazole.
DB01016
Aminosalicylic acid may increase the hypoglycemic activities of Glyburide.
DB01067
Aminosalicylic acid may increase the hypoglycemic activities of Glipizide.
DB01120
Aminosalicylic acid may increase the hypoglycemic activities of Gliclazide.
DB01124
Aminosalicylic acid may increase the hypoglycemic activities of Tolbutamide.
DB01132
Aminosalicylic acid may increase the hypoglycemic activities of Pioglitazone.
DB01200
Aminosalicylic acid may increase the hypoglycemic activities of Bromocriptine.
DB01251
Aminosalicylic acid may increase the hypoglycemic activities of Gliquidone.
DB01252
Aminosalicylic acid may increase the hypoglycemic activities of Mitiglinide.
DB01261
Aminosalicylic acid may increase the hypoglycemic activities of Sitagliptin.
DB01268
Aminosalicylic acid may increase the hypoglycemic activities of Sunitinib.
DB01276
Aminosalicylic acid may increase the hypoglycemic activities of Exenatide.
DB01277
Aminosalicylic acid may increase the hypoglycemic activities of Mecasermin.
DB01278
Aminosalicylic acid may increase the hypoglycemic activities of Pramlintide.
DB01289
Aminosalicylic acid may increase the hypoglycemic activities of Glisoxepide.
DB01306
Aminosalicylic acid may increase the hypoglycemic activities of Insulin aspart.
DB01307
Aminosalicylic acid may increase the hypoglycemic activities of Insulin detemir.
DB01309
Aminosalicylic acid may increase the hypoglycemic activities of Insulin glulisine.
DB01382
Aminosalicylic acid may increase the hypoglycemic activities of Glymidine.
DB01700
Aminosalicylic acid may increase the hypoglycemic activities of AICA ribonucleotide.
DB04830
Aminosalicylic acid may increase the hypoglycemic activities of Buformin.
DB04876
Aminosalicylic acid may increase the hypoglycemic activities of Vildagliptin.
DB04878
Aminosalicylic acid may increase the hypoglycemic activities of Voglibose.
DB05115
Aminosalicylic acid may increase the hypoglycemic activities of NN344.
DB05819
Aminosalicylic acid may increase the hypoglycemic activities of NBI-6024.
DB06011
Aminosalicylic acid may increase the hypoglycemic activities of AMG-222.
DB06127
Aminosalicylic acid may increase the hypoglycemic activities of Bisegliptin.
DB06203
Aminosalicylic acid may increase the hypoglycemic activities of Alogliptin.
DB06292
Aminosalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
DB06335
Aminosalicylic acid may increase the hypoglycemic activities of Saxagliptin.
DB06655
Aminosalicylic acid may increase the hypoglycemic activities of Liraglutide.
DB08382
Aminosalicylic acid may increase the hypoglycemic activities of Gosogliptin.
DB08882
Aminosalicylic acid may increase the hypoglycemic activities of Linagliptin.
DB08907
Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.
DB08962
Aminosalicylic acid may increase the hypoglycemic activities of Glibornuride.
DB09022
Aminosalicylic acid may increase the hypoglycemic activities of Benfluorex.
DB09038
Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.
DB09043
Aminosalicylic acid may increase the hypoglycemic activities of Albiglutide.
DB09045
Aminosalicylic acid may increase the hypoglycemic activities of Dulaglutide.
DB09198
Aminosalicylic acid may increase the hypoglycemic activities of Lobeglitazone.
DB09199
Aminosalicylic acid may increase the hypoglycemic activities of Netoglitazone.
DB09200
Aminosalicylic acid may increase the hypoglycemic activities of Rivoglitazone.
DB09201
Aminosalicylic acid may increase the hypoglycemic activities of Ciglitazone.
DB09265
Aminosalicylic acid may increase the hypoglycemic activities of Lixisenatide.
DB09456
Aminosalicylic acid may increase the hypoglycemic activities of Insulin beef.
DB09564
Aminosalicylic acid may increase the hypoglycemic activities of Insulin degludec.
DB11567
Aminosalicylic acid may increase the hypoglycemic activities of Insulin peglispro.
DB11568
Aminosalicylic acid may increase the hypoglycemic activities of Insulin tregopil.
DB11698
Aminosalicylic acid may increase the hypoglycemic activities of Ipragliflozin.
DB11723
Aminosalicylic acid may increase the hypoglycemic activities of Dutogliptin.
DB11780
Aminosalicylic acid may increase the hypoglycemic activities of Allicin.
DB11824
Aminosalicylic acid may increase the hypoglycemic activities of Tofogliflozin.
DB11827
Aminosalicylic acid may increase the hypoglycemic activities of Ertugliflozin.
DB11898
Aminosalicylic acid may increase the hypoglycemic activities of 2,4-thiazolidinedione.
DB11950
Aminosalicylic acid may increase the hypoglycemic activities of Teneligliptin.
DB11992
Aminosalicylic acid may increase the hypoglycemic activities of Omarigliptin.
DB12268
Aminosalicylic acid may increase the hypoglycemic activities of Carmegliptin.
DB12412
Aminosalicylic acid may increase the hypoglycemic activities of Gemigliptin.
DB12417
Aminosalicylic acid may increase the hypoglycemic activities of Anagliptin.
DB12625
Aminosalicylic acid may increase the hypoglycemic activities of Evogliptin.
DB12713
Aminosalicylic acid may increase the hypoglycemic activities of Sotagliflozin.
DB12781
Aminosalicylic acid may increase the hypoglycemic activities of Balaglitazone.
DB12935
Aminosalicylic acid may increase the hypoglycemic activities of Remogliflozin etabonate.
DB13406
Aminosalicylic acid may increase the hypoglycemic activities of Carbutamide.
DB13446
Aminosalicylic acid may increase the hypoglycemic activities of Guar gum.
DB13675
Aminosalicylic acid may increase the hypoglycemic activities of Metahexamide.
DB13928
Aminosalicylic acid may increase the hypoglycemic activities of Semaglutide.
DB14027
Aminosalicylic acid may increase the hypoglycemic activities of Taspoglutide.
DB14035
Aminosalicylic acid may increase the hypoglycemic activities of Englitazone.
DB15171
Aminosalicylic acid may increase the hypoglycemic activities of Tirzepatide.
DB15217
Aminosalicylic acid may increase the hypoglycemic activities of Gastric inhibitory polypeptide.
DB00178
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Ramipril.
DB00492
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Fosinopril.
DB00519
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Trandolapril.
DB00542
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Benazepril.
DB00584
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Enalapril.
DB00691
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Moexipril.
DB00722
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Lisinopril.
DB00790
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Perindopril.
DB00881
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Quinapril.
DB00886
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Omapatrilat.
DB01180
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Rescinnamine.
DB01197
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Captopril.
DB01340
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Cilazapril.
DB01348
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Spirapril.
DB08836
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Temocapril.
DB09477
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Enalaprilat.
DB11783
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Imidapril.
DB13166
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Zofenopril.
DB13312
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Delapril.
DB14125
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Benazeprilat.
DB14207
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Fosinoprilat.
DB14208
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Ramiprilat.
DB14209
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Trandolaprilat.
DB14210
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Moexiprilat.
DB14213
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Perindoprilat.
DB14217
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Quinaprilat.
DB14231
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Quinoline Yellow WS.
DB15565
The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Cilazaprilat.
DB00214
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Torasemide.
DB00887
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Bumetanide.
DB00903
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Etacrynic acid.
DB02925
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Piretanide.
DB08961
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Azosemide.
DB00311
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Ethoxzolamide.
DB00703
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Methazolamide.
DB00819
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Acetazolamide.
DB00909
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Zonisamide.
DB01144
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Diclofenamide.
DB00936
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Salicylic acid.
DB01250
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Olsalazine.
DB01294
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Bismuth subsalicylate.
DB06251
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Dersalazine.
DB06807
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Phenyl aminosalicylate.
DB09543
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Methyl salicylate.
DB13509
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Aloxiprin.
DB13538
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Guacetisal.
DB13612
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Carbaspirin calcium.
DB14006
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Choline salicylate.
DB14026
The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Thiosalicylic acid.
DB00313
The serum concentration of Valproic acid can be increased when it is combined with Aminosalicylic acid.
DB00159
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Icosapent.
DB00244
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Mesalazine.
DB00328
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Indomethacin.
DB00461
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Nabumetone.
DB00465
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Ketorolac.
DB00469
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Tenoxicam.
DB00500
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Tolmetin.
DB00554
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Piroxicam.
DB00573
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Fenoprofen.
DB00586
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Diclofenac.
DB00605
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Sulindac.
DB00712
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Flurbiprofen.
DB00749
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Etodolac.
DB00784
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Mefenamic acid.
DB00788
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Naproxen.
DB00795
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Sulfasalazine.
DB00812
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Phenylbutazone.
DB00814
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Meloxicam.
DB00821
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Carprofen.
DB00861
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Diflunisal.
DB00870
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Suprofen.
DB00939
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Meclofenamic acid.
DB00945
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Acetylsalicylic acid.
DB00963
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Bromfenac.
DB00991
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Oxaprozin.
DB01014
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Balsalazide.
DB01397
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Magnesium salicylate.
DB01399
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Salsalate.
DB01401
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Choline magnesium trisalicylate.
DB01419
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Antrafenine.
DB01435
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Antipyrine.
DB01600
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Tiaprofenic acid.
DB06725
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Lornoxicam.
DB06736
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Aceclofenac.
DB06802
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Nepafenac.
DB09213
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Dexibuprofen.
DB09215
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Droxicam.
DB11079
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Trolamine salicylate.
DB13346
The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Bufexamac.
DB00343
The risk or severity of bleeding can be increased when Diltiazem is combined with Aminosalicylic acid.
DB00661
The risk or severity of bleeding can be increased when Verapamil is combined with Aminosalicylic acid.
DB00180
The serum concentration of Flunisolide can be decreased when it is combined with Aminosalicylic acid.
DB00443
The serum concentration of Betamethasone can be decreased when it is combined with Aminosalicylic acid.
DB00620
The serum concentration of Triamcinolone can be decreased when it is combined with Aminosalicylic acid.
DB00635
The serum concentration of Prednisone can be decreased when it is combined with Aminosalicylic acid.
DB00687
The serum concentration of Fludrocortisone can be decreased when it is combined with Aminosalicylic acid.
DB00741
The serum concentration of Hydrocortisone can be decreased when it is combined with Aminosalicylic acid.
DB00860
The serum concentration of Prednisolone can be decreased when it is combined with Aminosalicylic acid.
DB00959
The serum concentration of Methylprednisolone can be decreased when it is combined with Aminosalicylic acid.
DB01108
The serum concentration of Trilostane can be decreased when it is combined with Aminosalicylic acid.
DB01222
The serum concentration of Budesonide can be decreased when it is combined with Aminosalicylic acid.
DB01234
The serum concentration of Dexamethasone can be decreased when it is combined with Aminosalicylic acid.
DB01285
The serum concentration of Corticotropin can be decreased when it is combined with Aminosalicylic acid.
DB01380
The serum concentration of Cortisone acetate can be decreased when it is combined with Aminosalicylic acid.
DB01384
The serum concentration of Paramethasone can be decreased when it is combined with Aminosalicylic acid.
DB04630
The serum concentration of Aldosterone can be decreased when it is combined with Aminosalicylic acid.
DB09378
The serum concentration of Fluprednisolone can be decreased when it is combined with Aminosalicylic acid.
DB09383
The serum concentration of Meprednisone can be decreased when it is combined with Aminosalicylic acid.
DB11529
The serum concentration of Melengestrol can be decreased when it is combined with Aminosalicylic acid.
DB11921
The serum concentration of Deflazacort can be decreased when it is combined with Aminosalicylic acid.
DB13003
The serum concentration of Cortivazol can be decreased when it is combined with Aminosalicylic acid.
DB13208
The serum concentration of Prednylidene can be decreased when it is combined with Aminosalicylic acid.
DB13843
The serum concentration of Cloprednol can be decreased when it is combined with Aminosalicylic acid.
DB14681
The serum concentration of Cortisone can be decreased when it is combined with Aminosalicylic acid.
DB12768
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Aminosalicylic acid.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Aminosalicylic acid.
DB00063
The risk or severity of bleeding can be increased when Eptifibatide is combined with Aminosalicylic acid.
DB00208
The risk or severity of bleeding can be increased when Ticlopidine is combined with Aminosalicylic acid.
DB00758
The risk or severity of bleeding can be increased when Clopidogrel is combined with Aminosalicylic acid.
DB00775
The risk or severity of bleeding can be increased when Tirofiban is combined with Aminosalicylic acid.
DB00806
The risk or severity of bleeding can be increased when Pentoxifylline is combined with Aminosalicylic acid.
DB01138
The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Aminosalicylic acid.
DB01166
The risk or severity of bleeding can be increased when Cilostazol is combined with Aminosalicylic acid.
DB01207
The risk or severity of bleeding can be increased when Ridogrel is combined with Aminosalicylic acid.
DB01236
The risk or severity of bleeding can be increased when Sevoflurane is combined with Aminosalicylic acid.
DB02709
The risk or severity of bleeding can be increased when Resveratrol is combined with Aminosalicylic acid.
DB04743
The risk or severity of bleeding can be increased when Nimesulide is combined with Aminosalicylic acid.
DB04905
The risk or severity of bleeding can be increased when Tesmilifene is combined with Aminosalicylic acid.
DB05266
The risk or severity of bleeding can be increased when Ibudilast is combined with Aminosalicylic acid.
DB05767
The risk or severity of bleeding can be increased when Andrographolide is combined with Aminosalicylic acid.
DB06081
The risk or severity of bleeding can be increased when Caplacizumab is combined with Aminosalicylic acid.
DB07615
The risk or severity of bleeding can be increased when Tranilast is combined with Aminosalicylic acid.
DB08887
The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Aminosalicylic acid.
DB09283
The risk or severity of bleeding can be increased when Trapidil is combined with Aminosalicylic acid.
DB12092
The risk or severity of bleeding can be increased when Naftopidil is combined with Aminosalicylic acid.
DB12163
The risk or severity of bleeding can be increased when Sarpogrelate is combined with Aminosalicylic acid.
DB12321
The risk or severity of bleeding can be increased when Ifetroban is combined with Aminosalicylic acid.
DB12445
The risk or severity of bleeding can be increased when Nitroaspirin is combined with Aminosalicylic acid.
DB12465
The risk or severity of bleeding can be increased when Ketanserin is combined with Aminosalicylic acid.
DB12545
The risk or severity of bleeding can be increased when Indobufen is combined with Aminosalicylic acid.
DB12749
The risk or severity of bleeding can be increased when Butylphthalide is combined with Aminosalicylic acid.
DB12771
The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Aminosalicylic acid.
DB13036
The risk or severity of bleeding can be increased when Ramatroban is combined with Aminosalicylic acid.
DB13327
The risk or severity of bleeding can be increased when Picotamide is combined with Aminosalicylic acid.
DB13367
The risk or severity of bleeding can be increased when Cloricromen is combined with Aminosalicylic acid.
DB13400
The risk or severity of bleeding can be increased when Linsidomine is combined with Aminosalicylic acid.
DB13510
The risk or severity of bleeding can be increased when Buflomedil is combined with Aminosalicylic acid.
DB13929
The risk or severity of bleeding can be increased when Relcovaptan is combined with Aminosalicylic acid.
DB00261
The risk or severity of bleeding can be increased when Anagrelide is combined with Aminosalicylic acid.
DB10076
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.
DB10342
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Aminosalicylic acid.
DB10600
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB10794
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.
DB10990
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.
DB11038
The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB11040
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB11041
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB11044
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB14384
The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.
DB14385
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.
DB14394
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen is combined with Aminosalicylic acid.
DB14445
The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.
DB14449
The risk or severity of adverse effects can be increased when Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen is combined with Aminosalicylic acid.
DB14619
The risk or severity of adverse effects can be increased when Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB14620
The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) is combined with Aminosalicylic acid.
DB09413
The serum concentration of Aminosalicylic acid can be increased when it is combined with Monopotassium phosphate.
DB10318
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Varicella Zoster Vaccine (Live/attenuated).
DB01045
Aminosalicylic acid can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Aminosalicylic acid.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Aminosalicylic acid.
DB00279
The therapeutic efficacy of Liothyronine can be increased when used in combination with Aminosalicylic acid.
DB00451
The therapeutic efficacy of Levothyroxine can be increased when used in combination with Aminosalicylic acid.
DB01583
The therapeutic efficacy of Liotrix can be increased when used in combination with Aminosalicylic acid.
DB03604
The therapeutic efficacy of Tiratricol can be increased when used in combination with Aminosalicylic acid.
DB09100
The therapeutic efficacy of Thyroid, porcine can be increased when used in combination with Aminosalicylic acid.
DB00017
The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Aminosalicylic acid.
DB00066
The therapeutic efficacy of Follitropin can be decreased when used in combination with Aminosalicylic acid.
DB00389
The therapeutic efficacy of Carbimazole can be decreased when used in combination with Aminosalicylic acid.
DB00550
The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aminosalicylic acid.
DB00763
The therapeutic efficacy of Methimazole can be decreased when used in combination with Aminosalicylic acid.
DB03374
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Aminosalicylic acid.
DB05084
The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Aminosalicylic acid.
DB05829
The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Aminosalicylic acid.
DB06285
The therapeutic efficacy of Teriparatide can be decreased when used in combination with Aminosalicylic acid.
DB06715
The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Aminosalicylic acid.
DB07637
The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Aminosalicylic acid.
DB09418
The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Aminosalicylic acid.
DB09421
The therapeutic efficacy of Protirelin can be decreased when used in combination with Aminosalicylic acid.
DB12629
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Aminosalicylic acid.
DB13644
The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Aminosalicylic acid.
DB13742
The therapeutic efficacy of Elcatonin can be decreased when used in combination with Aminosalicylic acid.
DB13804
The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Aminosalicylic acid.
DB15263
The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Aminosalicylic acid.
DB00316
The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aminosalicylic acid.
DB09288
The risk or severity of adverse effects can be increased when Propacetamol is combined with Aminosalicylic acid.
DB00695
The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Furosemide.
DB00252
The protein binding of Phenytoin can be decreased when combined with Aminosalicylic acid.
DB01320
The protein binding of Fosphenytoin can be decreased when combined with Aminosalicylic acid.
DB00869
The risk or severity of metabolic acidosis can be increased when Dorzolamide is combined with Aminosalicylic acid.
DB14513
The serum concentration of Magnesium can be decreased when it is combined with Aminosalicylic acid.
DB14443
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Aminosalicylic acid.

序列

实验性质

Water Solubility
1690 mg/L (at 23 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
Melting Point
150.5 dec °C
PhysProp
logP
0.89
SANGSTER (1994)
pKa
2.05 (at 25 °C)
KORTUM,G ET AL (1961)

外部标识符

resource：Drugs Product Database (DPD)
identifier：6620
resource：ChEBI
identifier：27565
resource：PubChem Compound
identifier：4649
resource：PubChem Substance
identifier：46505572
resource：KEGG Compound
identifier：C02518
resource：KEGG Drug
identifier：D00162
resource：ChemSpider
identifier：4488
resource：BindingDB
identifier：48319
resource：PharmGKB
identifier：PA448382
resource：PDB
identifier：BHA
resource：Wikipedia
identifier：4-Aminosalicylic_acid
resource：ChEMBL
identifier：CHEMBL1169
resource：ZINC
identifier：ZINC000000000922
resource：RxCUI
identifier：7833

外部链接

RxList
http://www.rxlist.com/cgi/generic2/paser.htm
Drugs.com
http://www.drugs.com/cdi/aminosalicylic-acid-controlled-release-granules-packet.html

路径

目标

id:BE0000262
name:Prostaglandin G/H synthase 2
organism:Humans
action:inhibitor
Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.
Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.
Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.
Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.
Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.
known-action:unknown
name:Prostaglandin G/H synthase 2
general-function:Prostaglandin-endoperoxide synthase activity
specific-function:Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.
gene-name:PTGS2
locus:1q25.2-q25.3
cellular-location:Microsome membrane
transmembrane-regions:
signal-regions:1-17
theoretical-pi:7.41
molecular-weight:68995.625
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:9605GenAtlasPTGS2GenBank Gene DatabaseL15326GenBank Protein Database291988Guide to Pharmacology1376UniProtKBP35354UniProt AccessionPGH2_HUMAN
synonyms:1.14.99.1COX-2COX2Cyclooxygenase-2PGH synthase 2PGHS-2PHS IIProstaglandin H2 synthase 2Prostaglandin-endoperoxide synthase 2
amino-acid-sequence:>lcl|BSEQ0021832|Prostaglandin G/H synthase 2 MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER STEL
gene-sequence:>lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2) ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT TCGACTGAACTGTAG
pfams:PF03098An_peroxidasePF00008EGF
go-classifiers:componentcaveolacomponentcytoplasmcomponentendoplasmic reticulumcomponentendoplasmic reticulum lumencomponentendoplasmic reticulum membranecomponentneuron projectioncomponentnucleuscomponentprotein complexfunctionarachidonate 15-lipoxygenase activityfunctionenzyme bindingfunctionheme bindingfunctionlipid bindingfunctionmetal ion bindingfunctionperoxidase activityfunctionprostaglandin-endoperoxide synthase activityprocessangiogenesisprocessarachidonic acid metabolic processprocessbone mineralizationprocessbrown fat cell differentiationprocesscellular response to ATPprocesscellular response to fluid shear stressprocesscellular response to hypoxiaprocesscellular response to mechanical stimulusprocesscellular response to UVprocesscyclooxygenase pathwayprocessdecidualizationprocessembryo implantationprocesshair cycleprocessinflammatory responseprocesslearningprocesslipoxygenase pathwayprocessmaintenance of blood-brain barrierprocessmemoryprocessmovement of cell or subcellular componentprocessNAD metabolic processprocessnegative regulation of calcium ion transportprocessnegative regulation of cell cycleprocessnegative regulation of cell proliferationprocessnegative regulation of smooth muscle contractionprocessnegative regulation of synaptic transmission, dopaminergicprocessnicotinamide metabolic processprocessovulationprocesspositive regulation of apoptotic processprocesspositive regulation of brown fat cell differentiationprocesspositive regulation of cell migration involved in sprouting angiogenesisprocesspositive regulation of fever generationprocesspositive regulation of fibroblast growth factor productionprocesspositive regulation of NF-kappaB import into nucleusprocesspositive regulation of nitric oxide biosynthetic processprocesspositive regulation of platelet-derived growth factor productionprocesspositive regulation of prostaglandin biosynthetic processprocesspositive regulation of smooth muscle cell proliferationprocesspositive regulation of smooth muscle contractionprocesspositive regulation of synaptic plasticityprocesspositive regulation of synaptic transmission, glutamatergicprocesspositive regulation of transforming growth factor beta productionprocesspositive regulation of vascular endothelial growth factor productionprocesspositive regulation of vasoconstrictionprocessprostaglandin biosynthetic processprocessprostaglandin metabolic processprocessregulation of blood pressureprocessregulation of inflammatory responseprocessresponse to drugprocessresponse to estradiolprocessresponse to fatty acidprocessresponse to fructoseprocessresponse to glucocorticoidprocessresponse to lipopolysaccharideprocessresponse to lithium ionprocessresponse to manganese ionprocessresponse to oxidative stressprocessresponse to tumor necrosis factorprocessresponse to vitamin Dprocesssensory perception of painprocesssmall molecule metabolic processprocessvitamin metabolic processprocesswater-soluble vitamin metabolic process
id:BE0004655
name:Inhibitor of nuclear factor kappa-B kinase subunit alpha
organism:Humans
action:inhibitor
Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7.
Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.
Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18.
known-action:unknown
name:Inhibitor of nuclear factor kappa-B kinase subunit alpha
general-function:Scaffold protein binding
specific-function:Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor (PubMed:15084260).
gene-name:CHUK
locus:
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:
molecular-weight:84638.88
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:1974Guide to Pharmacology1989UniProtKBO15111UniProt AccessionIKKA_HUMAN
synonyms:2.7.11.10Conserved helix-loop-helix ubiquitous kinaseI-kappa-B kinase 1I-kappa-B kinase alphaIKK1IKKANFKBIKANuclear factor NF-kappa-B inhibitor kinase alphaTCF-16TCF16Transcription factor 16
amino-acid-sequence:>lcl|BSEQ0013242|Inhibitor of nuclear factor kappa-B kinase subunit alpha MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCH EIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQ ILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTS FVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPK CIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRC FVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGI SLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPI IQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKL EFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAE IMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRV LKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQ SSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHL STIIHEANEEQGNSMMNLDWSWLTE
gene-sequence:>lcl|BSEQ0013243|Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK) ATGGAGCGGCCCCCGGGGCTGCGGCCGGGCGCGGGCGGGCCCTGGGAGATGCGGGAGCGG CTGGGCACCGGCGGCTTCGGGAACGTCTGTCTGTACCAGCATCGGGAACTTGATCTCAAA ATAGCAATTAAGTCTTGTCGCCTAGAGCTAAGTACCAAAAACAGAGAACGATGGTGCCAT GAAATCCAGATTATGAAGAAGTTGAACCATGCCAATGTTGTAAAGGCCTGTGATGTTCCT GAAGAATTGAATATTTTGATTCATGATGTGCCTCTTCTAGCAATGGAATACTGTTCTGGA GGAGATCTCCGAAAGCTGCTCAACAAACCAGAAAATTGTTGTGGACTTAAAGAAAGCCAG ATACTTTCTTTACTAAGTGATATAGGGTCTGGGATTCGATATTTGCATGAAAACAAAATT ATACATCGAGATCTAAAACCTGAAAACATAGTTCTTCAGGATGTTGGTGGAAAGATAATA CATAAAATAATTGATCTGGGATATGCCAAAGATGTTGATCAAGGAAGTCTGTGTACATCT TTTGTGGGAACACTGCAGTATCTGGCCCCAGAGCTCTTTGAGAATAAGCCTTACACAGCC ACTGTTGATTATTGGAGCTTTGGGACCATGGTATTTGAATGTATTGCTGGATATAGGCCT TTTTTGCATCATCTGCAGCCATTTACCTGGCATGAGAAGATTAAGAAGAAGGATCCAAAG TGTATATTTGCATGTGAAGAGATGTCAGGAGAAGTTCGGTTTAGTAGCCATTTACCTCAA CCAAATAGCCTTTGTAGTTTAGTAGTAGAACCCATGGAAAACTGGCTACAGTTGATGTTG AATTGGGACCCTCAGCAGAGAGGAGGACCTGTTGACCTTACTTTGAAGCAGCCAAGATGT TTTGTATTAATGGATCACATTTTGAATTTGAAGATAGTACACATCCTAAATATGACTTCT GCAAAGATAATTTCTTTTCTGTTACCACCTGATGAAAGTCTTCATTCACTACAGTCTCGT ATTGAGCGTGAAACTGGAATAAATACTGGTTCTCAAGAACTTCTTTCAGAGACAGGAATT TCTCTGGATCCTCGGAAACCAGCCTCTCAATGTGTTCTAGATGGAGTTAGAGGCTGTGAT AGCTATATGGTTTATTTGTTTGATAAAAGTAAAACTGTATATGAAGGGCCATTTGCTTCC AGAAGTTTATCTGATTGTGTAAATTATATTGTACAGGACAGCAAAATACAGCTTCCAATT ATACAGCTGCGTAAAGTGTGGGCTGAAGCAGTGCACTATGTGTCTGGACTAAAAGAAGAC TATAGCAGGCTCTTTCAGGGACAAAGGGCAGCAATGTTAAGTCTTCTTAGATATAATGCT AACTTAACAAAAATGAAGAACACTTTGATCTCAGCATCACAACAACTGAAAGCTAAATTG GAGTTTTTTCACAAAAGCATTCAGCTTGACTTGGAGAGATACAGCGAGCAGATGACGTAT GGGATATCTTCAGAAAAAATGCTAAAAGCATGGAAAGAAATGGAAGAAAAGGCCATCCAC TATGCTGAGGTTGGTGTCATTGGATACCTGGAGGATCAGATTATGTCTTTGCATGCTGAA ATCATGGAGCTACAGAAGAGCCCCTATGGAAGACGTCAGGGAGACTTGATGGAATCTCTG GAACAGCGTGCCATTGATCTATATAAGCAGTTAAAACACAGACCTTCAGATCACTCCTAC AGTGACAGCACAGAGATGGTGAAAATCATTGTGCACACTGTGCAGAGTCAGGACCGTGTG CTCAAGGAGCTGTTTGGTCATTTGAGCAAGTTGTTGGGCTGTAAGCAGAAGATTATTGAT CTACTCCCTAAGGTGGAAGTGGCCCTCAGTAATATCAAAGAAGCTGACAATACTGTCATG TTCATGCAGGGAAAAAGGCAGAAAGAAATATGGCATCTCCTTAAAATTGCCTGTACACAG AGTTCTGCCCGGTCCCTTGTAGGATCCAGTCTAGAAGGTGCAGTAACCCCTCAGACATCA GCATGGCTGCCCCCGACTTCAGCAGAACATGATCATTCTCTGTCATGTGTGGTAACTCCT CAAGATGGGGAGACTTCAGCACAAATGATAGAAGAAAATTTGAACTGCCTTGGCCATTTA AGCACTATTATTCATGAGGCAAATGAGGAACAGGGCAATAGTATGATGAATCTTGATTGG AGTTGGTTAACAGAATGA
pfams:PF00069PkinasePF12179IKKbetaNEMObind
go-classifiers:componentCD40 receptor complexcomponentcytoplasmcomponentcytoplasmic side of plasma membranecomponentcytosolcomponentIkappaB kinase complexcomponentintracellular membrane-bounded organellecomponentnucleoplasmfunctionATP bindingfunctionIkappaB kinase activityfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionprotein kinase activityfunctionscaffold protein bindingprocessanatomical structure morphogenesisprocesscell surface receptor signaling pathwayprocesscellular response to tumor necrosis factorprocessepidermal growth factor receptor signaling pathwayprocessFc-epsilon receptor signaling pathwayprocessfibroblast growth factor receptor signaling pathwayprocessI-kappaB kinase/NF-kappaB signalingprocessI-kappaB phosphorylationprocessimmune responseprocessinflammatory responseprocessinnate immune responseprocesslactationprocessmammary gland alveolus developmentprocessmammary gland epithelial cell proliferationprocessmorphogenesis of an epithelial sheetprocessMyD88-dependent toll-like receptor signaling pathwayprocessMyD88-independent toll-like receptor signaling pathwayprocessneurotrophin TRK receptor signaling pathwayprocessNIK/NF-kappaB signalingprocessnucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayprocessnucleotide-binding oligomerization domain containing signaling pathwayprocessodontogenesis of dentin-containing toothprocessosteoclast differentiationprocessphosphatidylinositol-mediated signalingprocesspositive regulation of I-kappaB kinase/NF-kappaB signalingprocesspositive regulation of NF-kappaB transcription factor activityprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of type I interferon productionprocessprotein phosphorylationprocessregulation of tumor necrosis factor-mediated signaling pathwayprocessresponse to acetateprocessresponse to amino acidprocessresponse to drugprocessresponse to hydroperoxideprocessresponse to lipopolysaccharideprocessresponse to muscle stretchprocessresponse to toxic substanceprocessresponse to virusprocessRho protein signal transductionprocessskeletal muscle contractionprocessstimulatory C-type lectin receptor signaling pathwayprocessstress-activated MAPK cascadeprocessstriated muscle cell differentiationprocessT cell receptor signaling pathwayprocesstoll-like receptor 10 signaling pathwayprocesstoll-like receptor 2 signaling pathwayprocesstoll-like receptor 3 signaling pathwayprocesstoll-like receptor 4 signaling pathwayprocesstoll-like receptor 5 signaling pathwayprocesstoll-like receptor 9 signaling pathwayprocesstoll-like receptor signaling pathwayprocesstoll-like receptor TLR1processtoll-like receptor TLR6processTRIF-dependent toll-like receptor signaling pathwayprocesstumor necrosis factor-mediated signaling pathway
id:BE0000248
name:Arachidonate 5-lipoxygenase
organism:Humans
action:inhibitor
Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82.
Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51.
Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2.
known-action:unknown
name:Arachidonate 5-lipoxygenase
general-function:Iron ion binding
specific-function:Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
gene-name:ALOX5
locus:10q11.2
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:5.54
molecular-weight:77982.595
chromosome-location:10
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:435GenAtlasALOX5GenBank Gene DatabaseJ03600GenBank Protein Database187193Guide to Pharmacology1385UniProtKBP09917UniProt AccessionLOX5_HUMAN
synonyms:1.13.11.345-LOLOG5
amino-acid-sequence:>lcl|BSEQ0036979|Arachidonate 5-lipoxygenase MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDE ELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLA RDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVL NYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNG CNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDP CTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDF HVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECG LFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWE AIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYL TVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCW HLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPY YYLSPDRIPNSVAI
gene-sequence:>lcl|BSEQ0010032|Arachidonate 5-lipoxygenase (ALOX5) ATGCCCTCCTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGAC TACATCTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAG CCCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACGAG GAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAATGACGAC TGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGAGTTCCCCTGC TACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACGCGCAAAGTTGGCC CGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAGAACTGGAAACACGGCAA AAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCCTTGAGCATCGATGCCAAATGC CACAAGGATTTACCCCGTGATATCCAGTTTGATAGTGAAAAAGGAGTGGACTTTGTTCTG AATTACTCCAAAGCGATGGAGAACCTGTTCATCAACCGCTTCATGCACATGTTCCAGTCT TCTTGGAATGACTTCGCCGACTTTGAGAAAATCTTTGTCAAGATCAGCAACACTATTTCT GAGCGGGTCATGAATCACTGGCAGGAAGACCTGATGTTTGGCTACCAGTTCCTGAATGGC TGCAACCCTGTGTTGATCCGGCGCTGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACG GAGATGGTAGAGTGCAGCCTGGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGG AACATTTTCATCGTGGACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCC TGCACACTCCAGTTCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAG ATTGTCCCCATTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTC CCTTCGGATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTC CACGTCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGC ATTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCACAC GTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAGTGTGGC CTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGTGCAGAGGGCC ATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAAGGCCCGGGGCATG GAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACGGGCTCCTGGTGTGGGAA GCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTACTACGAGGGCGACCAGGTGGTG GAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGATGTCTACGTGTACGGCATGCGGGGC CGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAAGAGCCGGGAGCAGCTGTCGGAGTACCTG ACCGTGGTGATCTTCACCGCCTCCGCCCAGCACGCCGCGGTCAACTTCGGCCAGTACGAC TGGTGCTCCTGGATCCCCAATGCGCCCCCAACCATGCGAGCCCCGCCACCGACTGCCAAG GGCGTGGTGACCATTGAGCAGATCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGG CATCTGGGTGCAGTGTGGGCGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATG TACCCAGAAGAGCATTTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAG AACCTCGAGGCCATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATAT TACTACTTGTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGA
pfams:PF01477PLATPF00305Lipoxygenase
go-classifiers:componentcytosolcomponentdendritecomponentextracellular spacecomponentnuclear envelopecomponentnuclear envelope lumencomponentnuclear matrixcomponentnuclear membranecomponentsarcolemmafunctionarachidonate 5-lipoxygenase activityfunctioniron ion bindingprocessacute inflammatory responseprocessarachidonic acid metabolic processprocessleukotriene biosynthetic processprocessleukotriene metabolic processprocessleukotriene production involved in inflammatory responseprocesslipoxin metabolic processprocesslipoxygenase pathwayprocesspositive regulation of vasoconstrictionprocessresponse to hyperoxiaprocessresponse to nutrientprocesssensory perception of painprocesssmall molecule metabolic process
id:BE0003768
name:Group IIE secretory phospholipase A2
organism:Humans
action:unknown
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
known-action:unknown
name:Group IIE secretory phospholipase A2
general-function:Phospholipase a2 activity
specific-function:PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
gene-name:PLA2G2E
locus:1p36.13
cellular-location:Secreted
transmembrane-regions:
signal-regions:1-19
theoretical-pi:8.28
molecular-weight:15988.525
chromosome-location:1
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:13414GenBank Gene DatabaseAF189279GenBank Protein Database7108923Guide to Pharmacology1419UniProtKBQ9NZK7UniProt AccessionPA2GE_HUMAN
synonyms:3.1.1.4GIIE sPLA2Phosphatidylcholine 2-acylhydrolase 2E
amino-acid-sequence:>lcl|BSEQ0012632|Group IIE secretory phospholipase A2 MKSPHVLVFLCLLVALVTGNLVQFGVMIEKMTGKSALQYNDYGCYCGIGGSHWPVDQTDW CCHAHDCCYGRLEKLGCEPKLEKYLFSVSERGIFCAGRTTCQRLTCECDKRAALCFRRNL GTYNRKYAHYPNKLCTGPTPPC
gene-sequence:>lcl|BSEQ0012633|Group IIE secretory phospholipase A2 (PLA2G2E) ATGAAATCTCCCCACGTGCTGGTGTTCCTTTGCCTCCTGGTGGCTCTGGTCACCGGGAAC CTGGTTCAGTTTGGGGTGATGATCGAGAAGATGACAGGCAAGTCCGCCCTGCAGTACAAC GACTATGGCTGTTACTGCGGCATCGGTGGCTCCCACTGGCCGGTGGACCAGACTGACTGG TGCTGCCACGCCCACGACTGCTGCTACGGGCGTCTGGAGAAGCTGGGCTGTGAGCCCAAA CTGGAAAAGTATCTTTTCTCTGTCAGCGAACGTGGCATTTTCTGCGCCGGCAGGACCACC TGCCAGCGGCTGACCTGCGAGTGTGACAAGAGGGCTGCCCTCTGCTTTCGCCGCAACCTG GGCACCTACAACCGCAAATATGCCCATTATCCCAACAAGCTGTGCACCGGGCCCACCCCG CCCTGCTGA
pfams:PF00068Phospholip_A2_1
go-classifiers:componentextracellular regionfunctioncalcium ion bindingfunctionphospholipase A2 activityprocessglycerophospholipid biosynthetic processprocessinflammatory responseprocesslipid catabolic processprocessphosphatidic acid biosynthetic processprocessphosphatidylcholine acyl-chain remodelingprocessphosphatidylethanolamine acyl-chain remodelingprocessphosphatidylglycerol acyl-chain remodelingprocessphosphatidylinositol acyl-chain remodelingprocessphosphatidylserine acyl-chain remodelingprocessphospholipid metabolic processprocesssmall molecule metabolic process

酶

BE0001075MyeloperoxidaseHumansinhibitorA177762563347von Ritter C, Grisham MB, Granger DN: Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucyl-phenylalanine-induced mucosal injury in rat ileum. Gastroenterology. 1989 Mar;96(3):811-6.A1777716614956Gorgulu S, Yagci G, Kaymakcioglu N, Ozkara M, Kurt B, Ozcan A, Kaya O, Sadir S, Tufan T: Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci. 2006 Mar;51(3):480-7.unknownMyeloperoxidasePeroxidase activityPart of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.MPO17q23.1Lysosome1-489.1483867.7117HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:7218GenAtlasMPOGenBank Gene DatabaseJ02694GenBank Protein Database189040Guide to Pharmacology2789UniProtKBP05164UniProt AccessionPERM_HUMAN1.11.2.2MPO>lcl|BSEQ0002139|Myeloperoxidase MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS NSYPRDFVNCSTLPALNLASWREAS>lcl|BSEQ0016304|Myeloperoxidase (MPO) ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC TGGAGGGAAGCCTCCTAGPF03098An_peroxidasecomponentazurophil granulecomponentextracellular exosomecomponentextracellular spacecomponentlysosomecomponentmitochondrioncomponentnucleuscomponentsecretory granulefunctionchromatin bindingfunctionheme bindingfunctionheparin bindingfunctionmetal ion bindingfunctionperoxidase activityprocessdefense responseprocessdefense response to fungusprocesshydrogen peroxide catabolic processprocesshypochlorous acid biosynthetic processprocesslow-density lipoprotein particle remodelingprocessnegative regulation of apoptotic processprocessnegative regulation of growth of symbiont in hostprocessoxidation-reduction processprocessremoval of superoxide radicalsprocessrespiratory burst involved in defense responseprocessresponse to oxidative stressprocessresponse to yeastunknown

载体

运输工具

药物反应

效应

不良反应